Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen in Severe CFS/ME
NCT00215800Phase 3Completed
- Sponsor
- AIM ImmunoTech
- Start
- Dec 1998
- Primary completion
- Feb 2004
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
01
Overview
A Phase 3 trial of rintatolimod in myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS), myalgic encephalomyelitis (ME), sponsored by AIM ImmunoTech. Started Dec 1998; status: completed.
02
Drugs
rintatolimod
03
Conditions
myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on NCT00215800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215800.